JAK2 and myeloproliferative disorder: In a recent publication by Košťál M. et al. [20], the JAK2 V617F mutation was a significant risk factor for stroke/TIA events (OR—2.303, 1.275–4.159; p < 0.01) in a cohort of patients with MPD.